Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

ClinicalTrials.gov ID: NCT02178956

Public ClinicalTrials.gov record NCT02178956. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.

Study identification

NCT ID
NCT02178956
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Enrollment
714 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2014
Primary completion
Sep 19, 2017
Completion
Sep 19, 2017
Last update posted
Nov 14, 2023

2014 – 2017

United States locations

U.S. sites
26
U.S. states
17
U.S. cities
24
Facility City State ZIP Site status
Mayo Clinic - Arizona Scottsdale Arizona 85259
Colorado Cancer Research Program Denver Colorado 80222
Indiana University Health Goshen Center For Cancer Care Goshen Indiana 46526
Northern Indiana Cancer Research Consortium South Bend Indiana 46628
Siouxland Regional Cancer Center Sioux City Iowa 51101
Cancer Center of Kansas Wichita Kansas 67214
Ochsner NCI CORP New Orleans Louisiana 70121
Spectrum Health Butterworth Grand Rapids Michigan 49503
Munson Medical Center Traverse City Michigan 49684
Mayo Clinic - Rochester Rochester Minnesota 55905
Metro-Minnesota NCI CORP Saint Louis Park Minnesota 55416
Heartland NCORP St Louis Missouri 63131
New Hampshire Oncology Hematology - Concord Concord New Hampshire 03106
New Hampshire Oncology Hematology - Laconia Laconia New Hampshire 03246
Weill Medical College of Cornell University New York New York 10065
State University of New York Upstate Medical University Syracuse New York 13210
Indiana University Health University Hospital Chapel Hill North Carolina 27516
Ohio State University Medical Center Columbus Ohio 43210
The University of Oklahoma Health Sciences Center (OUHSC) Oklahoma City Oklahoma 73104
Geisinger Medical Center Danville Pennsylvania 17822
Virginia Mason Medical Center Seattle Washington 98101
Swedish Cancer Institute/ Swedish Health Services Seattle Washington 98104
Saint Vincent Hospital CCOP Green Bay Wisconsin 54301
St. Mary's Hospital Green Bay Wisconsin 54307
Gundersen Lutheran Medical Center La Crosse Wisconsin 54601
Marshfield CCOP Marshfield Wisconsin 54449

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 237 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02178956, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 14, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02178956 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →